Report - ANEXO I RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO · leucemia, interromper imatinib até ANC ≥ 1 x 10. 9 /l e as plaquetas ≥ 20 x 10. 9 /l e, depois, reiniciar o tratamento com

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form